Suchen
InflaRx NV
IFRXZur Watchlist hinzufügen
1.740USD
+0.010+0.58%
Handelsschluss 07-23 16:00（ET）Kurse um 15 Minuten verzögert
125.79MMarktkapitalisierung
VerlustKGV TTM
mehr Informationen über InflaRx NV Unternehmen
Inflarx NV, formerly Fireman BV, is a holding company for InflaRx GmbH, a Germany-based clinical-stage biopharmaceutical company. The Company's primary focus is on the development of monoclonal antibodies targeting activation products of the complement system for application in the treatment of life-threatening inflammatory diseases. Its lead product candidate, IFX-1, is an intravenously delivered first-in-class anti-C5a monoclonal antibody, undergoing Phase II clinical trial for the treatment of Hidradenitis Suppurativa (HS), a rare and chronic debilitating systemic inflammatory skin disease, and entering Phase II clinical trial for the treatment of ANCA-associated vasculitis (AAV) and other rare autoimmune diseases. The Company's product pipeline also includes IFX-2, which is in preclinical development.
InflaRx NV Informationen
BörsenkürzelIFRX
Name des UnternehmensInflaRx NV
IPO-datumNov 08, 2017
CEORiedemann (Niels C)
Anzahl der mitarbeiter74
WertpapierartOrdinary Share
GeschäftsjahresendeNov 08
AddresseWinzerlaer Str. 2
StadtJENA
BörseNASDAQ OMX - NASDAQ BASIC
LandGermany
Postleitzahl07745
Telefon493641508180
Websitehttps://www.inflarx.de/
BörsenkürzelIFRX
IPO-datumNov 08, 2017
CEORiedemann (Niels C)
Führungskräfte von InflaRx NV
Name
Name/Position
Position
Aktienbesitz
Veränderung
Mr. Nicolas Fulpius
Mr. Nicolas Fulpius
Independent Chairman of the Board
Independent Chairman of the Board
490.05K
+4.52%
Mr. Richard Brudnick
Mr. Richard Brudnick
Non-Executive Independent Director
Non-Executive Independent Director
50.00K
--
Dr. Thomas Taapken
Dr. Thomas Taapken
Chief Financial Officer
Chief Financial Officer
3.50K
--
Prof. Niels C. Riedemann, M.D., Ph.D
Prof. Niels C. Riedemann, M.D., Ph.D
Chief Executive Officer, Executive Director
Chief Executive Officer, Executive Director
--
--
Prof. Renfeng Guo
Prof. Renfeng Guo
Chief Scientific Officer, Executive Director
Chief Scientific Officer, Executive Director
--
--
Mr. Mark Kubler
Mr. Mark Kubler
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Mr. Anthony Gibney
Mr. Anthony Gibney
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Dr. Camilla Chong
Dr. Camilla Chong
Chief Medical Officer
Chief Medical Officer
--
--
Ms. Derval O'Carroll
Ms. Derval O'Carroll
Senior Vice President, Global Head of Regulatory Affairs and Compliance
Senior Vice President, Global Head of Regulatory Affairs and Compliance
--
--
Ms. Hege Hellstrom
Ms. Hege Hellstrom
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Name
Name/Position
Position
Aktienbesitz
Veränderung
Mr. Nicolas Fulpius
Mr. Nicolas Fulpius
Independent Chairman of the Board
Independent Chairman of the Board
490.05K
+4.52%
Mr. Richard Brudnick
Mr. Richard Brudnick
Non-Executive Independent Director
Non-Executive Independent Director
50.00K
--
Dr. Thomas Taapken
Dr. Thomas Taapken
Chief Financial Officer
Chief Financial Officer
3.50K
--
Prof. Niels C. Riedemann, M.D., Ph.D
Prof. Niels C. Riedemann, M.D., Ph.D
Chief Executive Officer, Executive Director
Chief Executive Officer, Executive Director
--
--
Prof. Renfeng Guo
Prof. Renfeng Guo
Chief Scientific Officer, Executive Director
Chief Scientific Officer, Executive Director
--
--
Mr. Mark Kubler
Mr. Mark Kubler
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Häufig gestellte Fragen
Wer sind die fünf größten Anteilseigner von InflaRx NV?
Die fünf größten Anteilseigner von InflaRx NV sind: Mr. Nicolas Fulpius
Wie viele Institutionen halten Anteile an InflaRx NV (IFRX)?
Mit Stand vom 2026Q1 halten 82 Institutionen Anteile an InflaRx NV, mit einem Gesamtmarktwert von etwa 19.59M, was 13.30% der Gesamtanteile entspricht. Im Vergleich zum 2025Q4 ist der institutionelle Aktienbesitz um -4596250.00 gestiegen.